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PARAOXONASE 1 GENE POLYMORPHISMS CONTRIBUTE TO 
CORONARY ARTERY DISEASE RISK AMONG NORTH INDIANS
S. AGRAWAL, GAURAV TRIPATHI, R. PRAJNYA, NAKUL SINHA1, A. GILMOUR2, L. BUSH2, 
S. MASTANA2  
ABSTRACT
BACKGROUND: Polymorphisms in paraoxonase 1 (PON1) coding for PON1 enzyme have 
been studied as genetic markers of coronary artery disease (CAD). PON1 Q192R and 
PON1 L55M polymorphisms have been analyzed extensively, but data on association 
and role of these polymorphisms in the etiology of CAD are conflicting. In this study, we 
tested the genetic association between PON1 Q192R and PON1 L55M polymorphisms 
and CAD among north Indians. MATERIALS AND METHODS: Two hundred eighty-five 
angiographically proven patients with coronary artery disease and 200 sex-matched 
and ethnically matched controls were genotyped for 2 PON1 polymorphisms by the 
polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) 
technique. Genotype/ allele frequencies were compared in patients and controls using 
the chi-square test. RESULTS: At PON1-192 locus, there were significant differences 
between patients and controls (P< 0.05), leading to significant odds ratios for RR 
genotype (OR= 1.92, CI: 1.19-3.10) and *R allele (OR= 1.30, CI: 1.00-1.70). These odds 
ratios were higher in the sub-sample of smokers (2.84 and 1.45, respectively). Binary 
logistic regression analysis also confirmed that *R allele carriers (QR and RR) have a 
higher risk of CAD (OR= 3.54, CI: 1.67-5.53). PON1-55 locus did not show significant 
differences between patients and controls, but LL genotype and *L allele were significant 
risk factors in the nonsmoker group. RL haplotype was also significantly associated with 
CAD risk (OR= 1.44, CI: 1.08-1.93). CONCLUSIONS: PON1-192R allele and RR genotype 
are significantly associated with CAD patients from the north Indian population (Uttar 
Pradesh). This association was stronger in smokers, supporting the conclusion that an 
interaction between PON1 activity and smoking augments CAD risk. Further studies 
with larger sample size are warranted to confirm these associations in different Indian 
populations. 
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INTRODUCTION 
Coronary artery disease (CAD) is a common, 
complex and multifactorial disorder and 
has become a major source of morbidity 
and mortal i ty in di f ferent parts of the 
world. [1-6] Genetic susceptibil ity to CAD 
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invo lves cont r ibut ion of  many genes 
involved in the metabolic pathways in the 
pathogenesis of atherosclerosis.[2-3] The 
prevalence of CAD varies widely among 
different geographical regions and ethnic 
groups. In urban India, the CAD rate is fourfold 
as compared to the rate in USA,[5] and it 
has become a prominent health problem in 
India.[6] Association and genome-wide studies 
have identified many candidate genes for 
CAD.[2] Some of these genes have been 
examined in Indian populations, including 
APOE, APOA1, GSTs, ACE, CCR5, TNFα, 
interleukins and CD14.[7-13] 
Paraoxonase 1 (PON1), a calcium-dependent 
antioxidant glycoprotein, is synthesized in the 
liver and secreted into the plasma, where it is 
associated with high density lipoproteins (HDL). 
Paraoxonase enzyme (EC 3.1.8.1) is implicated 
in lipid metabolism and in the elimination of 
carcinogenic lipid-soluble radicals.[14] PON1 is 
coded by the HUMPONA gene located on the 
chromosome 7 (7q 21.3-22.1).[15] Paraoxonase 
protects both low density lipoprotein (LDL) and 
HDL from oxidation. It prevents the formation 
of oxidized LDL (ox-LDL) and inactivates 
LDL-derived oxidized phospholipids and 
prevents oxidation of HDL phospholipids. 
Two coding polymorphisms of this gene 
 codon 192 and codon 55  have been 
studied for their association with CAD. At 
PON1-55, leucine is replaced by methionine 
(55L>M); and at PON1-192, glutamine is 
replaced by arginine (192Q>R). The 55L>M 
variant modulates PON1 concentration and 
level, and the Q192R variant is responsible 
fo r  i t s  ca ta l y t i c  ac t i v i t y .  PON1-192 
polymorphism gives rise to two alloenzymes: 
Q and R. QQ- and RR-homozygous individuals 
demonstrate lower- and higher-activity PON1 
respec t i ve l y . [16 -18 ]  The  PON1-Q192R 
polymorphism affects PON1 activity towards 
paraoxon, diazoxon, soman and sarin and 
is associated with coronary artery disease, 
stroke, familial hypercholesterolemia and type 2 
diabetes.[14-23] Some studies document that 
PON1-192 is involved in CAD risk only when 
other factors like diabetes, smoking and diet 
are present (19-23). Sanghera et al. [24,25] 
reported that the PON1-192*R allele is a risk 
factor for coronary heart disease (CHD) among 
Asian Indians in Singapore. Pati and Pati[26] 
reported a higher frequency of the QR and RR 
genotypes among Indian CAD patients.
The aim of the present study was to analyze 
genetic variation at the PON1-192 and PON1-
55 loci and to assess their genetic association 
with CAD in a north Indian population (Uttar 
Pradesh). This is a part of ongoing genetic 
investigat ions to untangle the genetic 
architecture of heart diseases in north India.
MATERIALS AND METHODS
Study design and population
Two hundred eighty-five angiographically 
proven CAD patients were included in the 
study. These patients were evaluated at the 
Department of Cardiology, and an experienced 
cardiologist performed all angiographic 
evaluations. Two hundred sex-matched healthy 
individuals from the institute staff were selected 
as controls after a detailed evaluation of history; 
clinical features; and investigations, including 
a treadmill test; to exclude presence of CAD. 
Controls with risk factors like family history 
of CAD, diabetes mellitus, hypertension and 
hyperlipidemia were excluded from the study. 
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Lipid proÞ le included total cholesterol (TC), 
triglycerides (TG), high-density lipoprotein 
(HDL) cholesterol and very low density 
lipoprotein cholesterol (VLDL), which were 
measured by the enzymatic method (chemistry 
autoanalyzer, Technicon RX-XT) both in the 
patient and control groups. The controls and 
patients were ethnically matched. Ethnicity 
was conÞ rmed by detailed questionnaire, and 
only those participants who were settled in 
Uttar Pradesh for the last 5 generations were 
included in the study. Genders of controls 
and patients were also matched; there were 
comparable numbers of males and females in 
both categories. Informed written consent was 
obtained from all subjects. The study protocol 
conforms to the ethical guidelines of the 1975 
Declaration of Helsinki. Ethical clearance was 
obtained following guidelines set down by the 
institutes (SGPGIMS) ethical committee.
Angiographic classifi cation
Angiographic criteria defining CAD cases 
were as follows: (1) lumen reduction ≥20% 
on one or more major epicardial coronary 
arteries; (2) lumen reduction 10%-19% in 
3 or more coronary artery segments. Mild 
coronary lesions were deÞ ned as <50% lumen 
narrowing; and moderate-to-severe coronary 
artery stenoses, ≥50% lumen narrowing.
Genotyping
Genomic DNA was extracted from whole blood 
using the salting-out method. PCR was used 
to amplify two loci of the PON1 gene from 100-
ng genomic DNA in a total reaction volume of 
20 µL, as described by Humbert et al.[16] and 
Sanghera et al.[25] The PCR was carried out 
with 2xReddyMix PCR Master Mix (Abgene) 
which contained 1.25 U Thermoprime Plus 
DNA polymerase, 75 mM Tris-HCl (pH, 8.8 
at 25°C), 20 mM (NH4)2SO4, 2.5 mM MgCl2, 
0.01% (v/v) Tween® 20, 0.2 mM each of dATP, 
dCTP, dGTP, dTTP precipitant and red dye 
for electrophoresis. Gel electrophoresis was 
carried out in 3% agarose gel. Alleles were 
scored independently by 2 researchers. Some 
samples (~3%, 10 patients and 5 controls) failed 
to amplify even after 3 attempts; therefore, these 
were not included in further analyses.
Statistical analysis
The Student t test was used to compare 
means for continuous variables. The chi-
square test was used to assess the Hardy-
Weinberg equilibrium. The odds ratios with 
95% confidence intervals were calculated 
using standard epidemiological/ association 
methods, and signiÞ cance was assessed by 
the chi-square test. All P values are two tailed, 
and P values < .05 were considered statistically 
signiÞ cant. To evaluate the synergistic effect 
of PON1 (-192, -55) gene polymorphisms and 
risk of CAD, we performed the multivariate 
analysis using the SPSS software (version 
11.5). Allele frequencies were calculated as 
the number of occurrences of the test allele in 
the population divided by the total number of 
alleles. The carriage rate was calculated as the 
number of individuals carrying at least one copy 
of the test allele divided by the total number of 
individuals. Bonferroni correction was used to 
correct the level of signiÞ cance. The sample size 
calculations showed that the present sample had 
enough power (>80%) to detect an odds ratio of 
around 1.5 or higher at alpha level of 5%. This 
was based on distribution of allele frequencies 
in previous studies. The haplotype frequency 
estimation was evaluated by using Arlequin 
version 3.1 software.
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RESULTS
Demographic and clinical characteristics of 
patients and controls
Patients and controls were evaluated for 13 
parameters as shown in Table 1. CAD patients 
were significantly older than the controls 
(P= 0.012). Two most important parameters, 
viz., serum HDL level and ApoB, showed 
signiÞ cant differences (P< 0.0001) between 
the two groups; however, total cholesterol, TG, 
LDL and VLDL (mg/dL) were also signiÞ cantly 
higher among the patients (P< 0.0001). The 
number of smokers in the patient group was 
greater when compared with that in the control 
group (P< 0.01).
There were no departures from the Hardy-
Weinberg equilibrium at either of the loci in 
any group. Table 2 describes the distribution 
of genotypes and allele frequencies and 
associated odds ratios with confidence 
intervals. It is clear that PON1-192 RR 
genotype and *R allele are significantly 
associated with CAD risk among north Indians. 
Susceptible LL genotype and *L allele of PON1-
Table 1: Demographic profi le and clinical 
characteristics of coronary artery disease patients 
and controls
Parameters (SI) Patients=285  Controls= 200 P Value
 (Mean ± SD) (Mean ± SD)
Age (Years) 47.49±11.86 44.58±13.36 0.012*
Gender (male/female) 244/41 163/37 0.276
Smokers (Yes/No) 183/102 105/95 0.013*
Diet (Non-veg/veg) 162/123 95/105 0.053
Hypertensive (No/Yes) 193/92 200/0 ..
Non-MI/MI 204/81 200/0 ..
S. Glucose (F) 
(mg/dL) 99.4±26.3 81.8±6.7 <0.0001*
S. TG (mg/dL) 207.09±108.9 139.64±60.84 <0.0001*
S. TC (mg/dL) 172.79±48.83 135.11±31.19 <0.0001*
S. HDL (mg/dL) 32.34±12.71 40.83±7.14 <0.0001*
S. LDL (mg/dL) 103.26±43.42 80.89±24.26 <0.0001*
S. VLDL (mg/dL) 40.81±17.49 28.89±12.39 <0.0001*
ApoB (mg/dL) 156.23±41.88 109.29±45.65 <0.0001*
*SigniÞ cant value (P< 0.05)
Table 2: Distribution of genotype and allele frequency of PON1-192 and PON1-55 polymorphisms in patients 
and controls
Genotype Patients  Controls  P Value OR (95% CI)
PON1-192 Q/R
Genotype Frequency
 n 275 195  
 QQ 74 (26.9) 58 (29.7) 0.56 0.87 (0.58-1.31)
 QR 132 (48.0) 108 (55.4) 0.14 0.74 (0.51-1.08)
 RR 69 (25.1) 29 (14.9) 0.01* 1.92 (1.19-3.1)
Allele Frequency
 Q allele 280 (50.9) 224 (57.4) 0.048* 1.30 (1.00-1.7)
 R allele 270 (49.1) 166 (42.6)  
Allele Carriage Frequency
 Q allele carriage 206 (74.9) 166 (85.1) 0.010* 0.52 (0.32-0.84)
 R allele carriage 201 (73.1) 137 (70.3) 0.569 1.15 (0.77-1.73)
PON1-55 L/M
Genotype Frequency
 n 279 190  
 LL 158 (56.6) 94 (49.5) 0.140 1.34 (0.93-1.95)
 LM 96 (34.4) 74 (39.0) 0.350 0.83 (0.56-1.21)
 MM 25 (9.0) 22 (11.5) 0.441 0.75 (0.41-1.38)
Allele Frequency
 L allele 412 (73.8) 262 (68.9) 0.119 1.27 (0.95-1.69)
 M allele 146 (26.2) 118 (31.1)  
Allele Carriage Frequency
 L allele carriage 254 (91.1) 168 (88.4) 0.441 0.75 (0.41-1.38)
 M allele carriage 121 (43.4) 96 (50.5) 0.152 1.33 (0.92-1.93)
*SigniÞ cant value (P< .05)
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55 locus showed higher odds ratios but failed to 
achieve statistical signiÞ cance.
Table 3 outlines the combined analysis of 
PON1-192 and PON1-55 genotypes and 
haplotype frequencies, along with associated 
odds ratios and P values. It is clear from this 
table that individuals with a genetic constitution 
of RR/ LL genotype have 2 times higher 
risk of CAD compared to other genotype 
combinations. Similarly, RL haplotype is 
signiÞ cantly associated with the disease. Other 
genotype and haplotype combinations failed 
to achieve statistical signiÞ cance even though 
odds ratios were higher, possibly due to small 
observed numbers in some cells. Caution is 
warranted in interpretations of these results. 
To demonstrate an independent role of PON1 
in influencing the risk of CAD, we have 
assessed the association between PON1 
genotypes and CAD risk using a multivariate 
model. In multivariate logistic regression 
analysis where CAD was a dependent variable 
and the two polymorphisms were independent 
variables, the PON1-192Q/R polymorphism 
revealed an association with CAD (P= 0.005), 
whereas the PON1-55L/M polymorphism 
association was not signiÞ cant (P= 0.2596) 
[Table 4]. Age, sex, alcohol consumption and 
HDL and ApoB concentrations were the other 
independent factors for CAD susceptibility in 
this population.
To assess if there was any interaction between 
smoking and PON1 polymorphisms, we 
classified genotypes according to smoking/ 
nonsmoking status and assessed the 
associated odds ratios; the results are 
Table 3: Combined analysis of PON1 genotypes among coronary artery disease patients and controls (genotype 
and haplotype distribution)
Genotype Patients (n=269) Controls (n=186) P Value OR (95% CI)
PON1-192 Q/R and PON1-55 L/M (Genotype distribution)
 QQ/LL 37 (13.7) 27 (14.5) 0.93 0.94 (0.55-1.60)
 QQ/LM 32 (11.9) 24 (12.9) 0.86 0.91 (0.52-1.60)
 QQ/MM 4 (1.5) 2 (1.1) 0.97 1.39 (0.25-7.66)
 QR/LL 78 (29.0) 52 (28.0) 0.89 1.05 (0.70-1.59)
 QR/LM 40 (14.9) 40 (21.5) 0.09 0.64 (0.39-1.04)
 QR/MM 11 (4.1) 14 (7.5) 0.17 0.52 (0.23-1.18)
 RR/LL 36 (13.4) 13 (7.0) 0.04* 2.06 (1.06-3.99)
 RR/LM 21 (7.8) 08 (4.3) 0.19 1.88 (0.82-4.35)
 RR/MM 10 (3.7) 06 (3.2) 0.98 1.16 (0.41-3.24)
PON1-192 Q/R and PON1-55 L/M (Haplotype distribution)
 QL 38% 41% 0.32 0.87 (0.67-1.43)
 RL 35% 27% 0.01* 1.44 (1.08-1.93)
 QM 13% 16% 0.27 0.80 (0.55-1.77)
 RM 14% 16% 0.40 0.85 (0.58-1.23)
*SigniÞ cant value (P< 0.05)
Table 4: Logistic regression analysis of determinants 
of coronary artery disease in patients
Variables P Value OR (95% CI)
Age (years) 0.0111* 2.56 (1.31-4.62)
Sex (M/F) <0.0001* 4.09 (2.83-6.43)
Smoking (Yes/No) 0.0847 1.73 (1.32-4.12)
Alcohol (Yes/No) <0.0001* 4.93 (3.34-7.02)
HDL (mg/dL) 0.0152* 2.45 (1.51-3.42)
LDL(mg/dL) 0.0782 0.29 (0.14-0.33)
TG(mg/dL) 0.3171 1.01 (0.57-2.34)
TC(mg/dL) 0.7594 0.31 (0.12-1.14) 
ApoB (mg/dL) 0.0472* 1.99 (0.67-3.01) 
Non-MI / MI 0.0568 0.17 (0.12-1.14)
VLDL(mg/dL) 0.1009 1.65 (0.61-2.59)
Hypertension (Yes/No) 0.9089 0.11 (0.10-1.11)
PON1-192 (QQ vs. QR+RR) 0.005* 3.54 (1.67-5.53)
PON1-55 (LL vs. LM+MM) 0.2596 1.13 (0.93-1.97)
*SigniÞ cant value (P< 0.05)
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presented in Table 5. It is clear from the table 
that PON1-192 polymorphism provides higher 
odds ratios (compared to the combined one) 
at genotype level among smokers; but at allele 
level, this effect is not signiÞ cant. At PON1-55 
locus, there is no interaction with smoking; but 
among nonsmokers, LM genotype seems to be 
protective and LL genotype and *L allele are 
susceptible.
DISCUSSION
Several previous studies have produced 
evidence to suggest that the PON1-192 and 
PON1-55 polymorphisms may be associated 
with CAD risk in the general population, due 
to PON1 enzymes role in lipid metabolism. 
However, this is the first study on these 
polymorphisms speciÞ cally on a homogenous 
population from north India to confirm and 
replicate the existence of a susceptible 
association between the PON1-192 and 
PON1-55 loci and CAD. These results are 
consistent with previous studies. SigniÞ cant 
association between the PON1-192 R (Arg) 
allele and CAD risk has been detected in Asian 
Indians,[24,26] North American Caucasians[27,28] 
and the Japanese population,[20] but not in 
Chinese,[24] Korean,[29] Spanish,[21] Italian,[30] 
British Caucasian[22,31] and Polish[32] populations. 
A meta-analysis of 43 genetic association 
studies conducted by Wheeler et al.[33] found 
that the per-allele relative risk of the R192 
variant to CHD was 1.12 (95% CI: 1.07-1.16), 
indicating a weak positive association. In the 
present study, odds ratios were slightly higher, 
suggesting that 192 R associations may be 
Table 5: Effect of PON1 (-192 and -55) genotypes on risk of CAD among smokers and nonsmokers
Smokers
PON1-192 Q/R  Patients (%) Controls (%) P Value OR 95% CI
 n 177 100   
 QQ  53 (29.9) 33 (33.0) 0.69 0.87 (0.51-1.47)
 QR  78 (44.1) 56 (56.0) 0.07 0.62 (0.38-1.01)
 RR  46 (26.0) 11 (11.0) 0.005* 2.84 (1.40-5.78)
 *Q 184 (52.0) 122 (61.0) 0.05 1.45 (1.02-2.06)
 *R  170 (48.0) 78 (39.0)   
PON1-55 L/M
 n 180 102   
 LL  97 (53.8) 57 (55.9) 0.84 0.92 (0.57-1.50)
 LM  66 (36.7) 33(32.3) 0.58 1.21 (0.72-2.02)
 MM  17 (9.4) 12 (11.8) 0.68 0.78 (0.36-1.71)
 *L  260 (72.2) 147 (72.1) 0.95 1.01 (0.69-1.48)
 *M  100 (27.8) 57 (27.9)   
Nonsmokers
PON1-192 Q/R  Patients Controls P Value OR 95% CI
 n 98 95   
 QQ  21 (21.4) 25 (26.3) 0.53 0.76 (0.39-1.48)
 QR 54 (55.1) 52 (54.8) 0.92 1.01 (0.58-1.79)
 RR 23 (23.5) 18 (18.9) 0.55 1.31 (0.66-2.63)
 *Q 96 (49.0) 102 (53.7) 0.41 1.21 (0.81-1.80)
 *R 100 (51.0) 88 (46.3)   
PON1-55 L/M
 n 99 88   
 LL  61 (61.6) 37 (42.0) 0.01* 2.21 (1.23-3.98)
 LM  30 (33.3) 41 (46.6) 0.03* 0.45 (0.27-0.89)
 MM  8 (8.1) 10 (11.4) 0.61 0.57 (0.26-1.82)
 L  152 (76.8) 115 (65.3) 0.02* 1.75 (1.11-2.76)
 M  46 (23.2) 61 (34.6)
*SigniÞ cant value (P<0.05)   
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stronger in speciÞ c populations, and our results 
are consistent with those of previous studies on 
Indian populations.[24,26] 
P O N 1  p r o t e i n  p l a y s  a  k e y  r o l e  i n 
organophosphate metabolism (widely used in 
insecticides and nerve gases); however, PON1 
has been linked to lipid metabolism also.[34] The 
link between PON1 activity and atherosclerosis 
is largely established by biological rather than 
epidemiological studies, as there is evidence 
that peroxidation of low-density lipoprotein 
cholesterol (LDL-C) is an important risk factor 
for atherosclerosis.[34-40] As oxidative damage 
is a major contributor to arteriolosclerosis, the 
oxidative modiÞ cation of LDL in the artery wall 
is an important factor in the development of 
CAD. Functional in vivo studies indicate that 
PON1 may prevent the development of CAD 
by being responsible for the ability of HDL 
to inhibit the oxidative modification of LDL 
particles into active atherogenic particles.[35,36] 
HDL-associated PON1 has been shown to 
impede the oxidation of LDL by inhibiting the 
formation of lipid peroxides.[37] The PON1-192 
polymorphism may be associated with an 
increased CAD risk due to the R (Arg) allele 
(high-activity R isoform) being less efÞ cient 
than the Q (Gln) allele (low-activity Q isoform) 
in reducing the oxidative modification of 
LDL, decreasing lipid peroxide hydrolysis.[14] 
However, it has also been suggested that the 
quality of the PON1 enzyme may be a better 
predictor of CHD risk than the PON1 genotype; 
because as compared to controls, patients 
consistently demonstrate lower PON1 activity 
and concentration levels, regardless of their 
PON1 genotype.[38-41]
The PON1-55 polymorphism is not extensively 
studied among Indian populations, and the 
present study results are consistent with those 
of the previous study by Sanghera et al.,[25] 
suggesting that PON1-55 has no independent 
effect on CAD. However, the LL and *L allele 
are signiÞ cantly associated with CAD among 
nonsmokers, which should be considered 
further with a large-population study. In the 
present study, haplotype combination R/L has a 
signiÞ cant susceptible effect, which is what one 
would expect in the light of the higher activity 
levels of these isoforms. 
There appears to  be a s t rong gene-
environment interaction in relation to the 
PON1-192 polymorphism and CAD. The 
environmental factors may mask or induce the 
atherogenic potential of the PON1-192 R (Arg) 
allele, thus modifying the effect of the PON1 
gene on CAD risk.[42] It is conceivable that the 
PON1-192 R allele has a more exaggerated 
effect on CAD risk for those living in high-risk 
environments of enhanced oxidative stress, 
such as smokers and those maintaining 
adverse dietary habits. In relation to smoking, 
in the present study, a larger proportion of 
patients smoked in comparison to controls 
(P< 0.05). The odds ratios for RR genotype are 
relatively higher in smokers and do not achieve 
significance among nonsmokers. Cigarette 
smoke contains many free radicals, and 
smokers generally have a lower antioxidative 
capacity than nonsmokers. Therefore, oxidized 
LDL particles from smokers generate more 
lipid peroxidation products than LDL from 
nonsmokers. Thus, it is possible that PON1 
activity has a more important protective 
role of lipid peroxidation in smokers than in 
nonsmokers.
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Other genetic factors that may explain the 
possible population-specific association 
between the PON1-192 R (Arg) allele and 
CAD risk include linkage disequilibrium (LD) 
and gene-gene interactions. It has been 
suggested that the PON1 gene closely interacts 
with members of its structurally similar multi-
gene family, PON2 and PON3, to modulate 
CAD risk at the gene level.[24,25] A population-
speciÞ c association may be explained through 
population differences in LD between the 
polymorphic sites of the PON genes, which 
arose through genetic drift or selective 
mechanisms.[29] In an Asian Indian population, 
Sanghera et al.[24,25] found CHD risk associated 
with the PON2*S allele to be confined to 
PON1-192 R allele carriers. This suggests 
an interaction between the distributions of 
genotypes at the two genes, acting together in 
relation to atherogenic molecules, which should 
be explored in further studies. It is possible 
that observed CAD associations are due to 
LD of PON1 and PON2 with PON3 or another 
nearby gene. It is also possible that there is 
an active association between the different 
polymorphisms within the coding and promoter 
region of the PON1 gene. 
The most obvious limitation of the present 
study is its sample size; though it had enough 
power to detect a moderate level of odds ratios 
of 1.5 or above, the allele frequency, ethnicity 
and subgrouping reduced the sample size to 
detect signiÞ cant effects further. However, the 
sample was well characterized and was from a 
homogenous Indian population, which reduces 
the risks of population stratiÞ cation and false 
associations.
When considered as a whole, the results of 
the present study on a north Indian population 
support and conÞ rm the association of PON-
192 RR genotype and *R allele with CAD in the 
general and smoker populations. The PON1-
55 LL genotype and *L allele are signiÞ cantly 
associated with CAD among nonsmokers, and 
susceptibility may be governed by different 
mechanisms at enzyme/ gene level. Further 
research is warranted on other populations 
from different parts of India to clarify if the PON 
loci are independent risk factors for CAD in the 
general — populations.
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